A Phase 1/2 interventional study of isatuximab SAR650984 and cemiplimab REGN2810 in Lymphoma, sponsored by Sanofi. Terminated at 20 sites in 7 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-09-23.
Sponsored by Sanofi · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Lymphoma by Sanofi — none open to participants now, none under way, none of them phase 3. Lymphoma · Sanofi.
Among the 17 studies in Lymphoma by Sanofi, this one is the 7th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2018, is the only one in phase 1/2, and was the 16th registered.
3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.
Browse Lymphoma studies →None of the 17 studies in Lymphoma by Sanofi is open now. The open studies under Lymphoma, anywhere →
Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 2 · Phase 4 2
First in 2003; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 58 is above the median of 43 across 2,319 interventional studies indexed under Lymphoma.
Median enrollment 55 across the 14 interventional studies, 262 across the 3 observational. Of the 17 that completed or were terminated, 2 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Lymphoma by Sanofi, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objectives:
Phase 1
-To characterize the safety and tolerability of isatuximab in combination with cemiplimab in participants with relapsed and refractory classic Hodgkin's lymphoma (cHL), diffuse large B-cell lymphoma (DLBCL) or peripheral T-cell lymphoma (PTCL), and to confirm the recommended Phase 2 dose (RP2D).
Phase 2
Secondary Objectives:
The total study duration per participant was up to 28 months, including an up to 28-day screening period, an up to 96-week treatment period, and a 90-day safety follow up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Classic Hodgkin's lymphoma (cHL), anti-programmed cell death protein 1/ligand 1 (PD-1/PD-L1) inhibitor naïve participants received isatuximab 10 milligrams per kilogram (mg/kg), intravenous (IV) infusion once a week (QW) in Cycle 1 and then every 2 weeks (Q2W) from Cycle 2 to Cycle 6 (each cycle of 28 days), and then every 3 weeks (Q3W) from Cycle 7 to Cycle 30 (each cycle of 21 days) along with cemiplimab 250 milligrams (mg) Q2W, IV infusion from Cycle 1 to 6 and then 350 mg Q3W from Cycle 7 to Cycle 30, with optional radiotherapy until, unacceptable adverse events (AEs) or participant's decision to stop the treatment, or at least 96 weeks (at least 48 weeks from initial signal of complete response \[CR\], whichever was longer) of delivery of investigational medicinal product(s) without documented progressive disease (PD), or study cut-off date, whichever occurs first (maximum duration: up to 103 weeks).
Drug: isatuximab SAR650984 · Drug: cemiplimab REGN2810
cHL, anti-PD-1/PD-L1 inhibitor progressor participants received isatuximab 10 mg/kg, IV infusion, QW in Cycle 1 and then Q2W from Cycle 2 to Cycle 6 (each cycle of 28 days) and Q3W from Cycle 7 to Cycle 30 (each cycle of 21 days) along with cemiplimab 250 mg Q2W, IV infusion from Cycle 1 to 6 and then 350 mg Q3W from Cycle 7 to Cycle 30, with optional radiotherapy until, unacceptable AEs or participant's decision to stop the treatment, or at least 96 weeks (at least 48 weeks from initial signal of CR, whichever was longer) of delivery of investigational medicinal product(s) without documented PD, or study cut-off date, whichever occurs first (maximum duration: up to 103 weeks).
Drug: isatuximab SAR650984 · Drug: cemiplimab REGN2810
Diffuse large B-cell lymphoma (DLBCL), anti PD-1/PD-L1 naïve participants received isatuximab 10 mg/kg, IV infusion, QW in Cycle 1 and then Q2W from Cycle 2 to Cycle 6 (each cycle of 28 days) and Q3W from Cycle 7 to Cycle 30 (each cycle of 21 days) along with cemiplimab 250 mg Q2W, IV infusion from Cycle 1 to 6 and then 350 mg Q3W from Cycle 7 to Cycle 30 until, unacceptable AEs or participant's decision to stop the treatment, or at least 96 weeks (at least 48 weeks from initial signal of CR, whichever was longer) of delivery of investigational medicinal product(s) without documented PD, or study cut-off date, whichever occurs first (maximum duration: up to 103 weeks).
Drug: isatuximab SAR650984 · Drug: cemiplimab REGN2810
Peripheral T-cell lymphoma (PTCL), anti PD-1/PD-L1 naïve participants received isatuximab 10 mg/kg, IV infusion, QW in Cycle 1 and then Q2W from Cycle 2 to Cycle 6 (each cycle of 28 days) and Q3W from Cycle 7 to Cycle 30 (each cycle of 21 days) along with cemiplimab 250 mg Q2W, IV infusion from Cycle 1 to 6 and then 350 mg Q3W from Cycle 7 to Cycle 30 until, unacceptable AEs or participant's decision to stop the treatment, or at least 96 weeks (at least 48 weeks from initial signal of CR, whichever was longer) of delivery of investigational medicinal product(s) without documented PD, or study cut-off date, whichever occurs first (maximum duration: up to 103 weeks).
Drug: isatuximab SAR650984 · Drug: cemiplimab REGN2810
Pharmaceutical form: solution for infusion Route of administration: intravenous
Also known as: Sarclisa
Pharmaceutical form: solution for infusion Route of administration: intravenous
Number of Participants With Dose Limiting Toxicities (DLTs)
DLTs: Adverse Events (AEs) occurring during 1st treatment cycle, unless due to disease progression or obviously unrelated cause which included: hematological abnormalities: Grade(G) 4 neutropenia(N) for 7 or more consecutive days, G3 to G4 N with fever (temperature greater than or equal to \[\>=\] 38.5 degree Celsius on more than 1 occasion) or microbiologically/radiographically documented infection, G3 to G4 thrombocytopenia with clinically significant bleeding requiring clinical intervention or non-hematological abnormalities: G 4 non-hematologic AE, G\>=2 uveitis, G3 non-hematological AE lasting greater than (\>)3 days, delay in initiation of Cycle 2 \>14 days due to treatment related laboratory abnormalities/AE. Any other AE that the study committee deemed to be dose-limiting, regardless of grade, was also considered as DLT.
Time frame: Cycle 1 (28 days)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), and Treatment-Emergent Serious Adverse Events (TESAEs)
An AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. Serious adverse events (SAEs) were any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as AEs that developed, worsened or became serious during the TEAE period (defined as the time from the first dose of study treatment up to 30 days after the last dose of study treatment).
Time frame: From first dose of study treatment up to 30 days after last dose of study treatment (maximum duration: up to 103 weeks)
Number of Participants With Laboratory Abnormalities: Hematological Parameters
Hematological parameters assessed were anemia, white blood cell (WBC) decreased, platelet count decreased, lymphocyte count decreased, and neutrophil count decreased. Abnormality criteria was assessed as per the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 NCI-CTCAE v 5.0), where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs.
Time frame: From first dose of study treatment up to 30 days after last dose of study treatment (maximum duration: up to 103 weeks)
Number of Participants With Laboratory Abnormalities: Electrolytes
Electrolyte parameters assessed were hyponatremia, hypokalemia, hyperkalemia, hypocalcemia, hypercalcemia, hypoalbuminemia, hypoglycemia and hyperglycemia. Abnormal criteria was assessed as per the NCI-CTCAE v 5.0, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs.
Time frame: From first dose of study treatment up to 30 days after last dose of study treatment (maximum duration: up to 103 weeks)
Number of Participants With Laboratory Abnormalities: Renal Parameters
Abnormal renal parameters assessed were glomerular filtration rate (GFR) by class, creatinine increased and hyperuricemia. GFR by class was assessed in categories:\>=90 milliliter per minute per 1.73 meter square (mL/min/1.73m\^2) (Normal), \>=60 to \<90 mL/min/1.73m\^2 (Mild), \>=30 to \<60 mL/min/1.73m\^2 (Moderate), \>=15 to \<30 mL/min/1.73m\^2 (Severe), and \<15 mL/min/1.73m\^2 (End Stage Renal Disease). Abnormal criteria was assessed as per NCI-CTCAE v 5.0, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs.
Time frame: From first dose of study treatment up to 30 days after last dose of study treatment (maximum duration: up to 103 weeks)
Number of Participants With Laboratory Abnormalities: Liver Function Parameters
Abnormal liver function parameters assessed were aspartate aminotransferase (AST) increased, alanine aminotransferase (ALT) increased, alkaline phosphatase (ALP) increased, blood bilirubin (BB) increased. Abnormal criteria was assessed as per NCI-CTCAE v 5.0, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs.
Time frame: From first dose of study treatment up to 30 days after last dose of study treatment (maximum duration: up to 103 weeks)
Cohort A1: Percentage of Participants With Complete Response (CR)
Percentage of participants who had a CR as a best overall response (BOR) using the Lugano response criteria (LRC) 2014 (based on PET-CT and CT responses). Per LRC, CR based on PET-CT response was defined as complete metabolic response (MR) in lymph nodes and extralymphatic sites with a score of 1, 2, or 3 with or without residual mass, on 5-point scale (5PS), where, 1= no uptake above background; 2 = uptake \<=mediastinum; 3 = uptake \> mediastinum but \<= liver; 4 = uptake moderately \> liver; 5 = uptake markedly higher than liver and/or new lesions; no new lesions and no evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow. CR based on CT-response was defined as target nodes/nodal masses of lymph nodes, extralymphatic sites regressed to \<=1.5 cm in longest dimension transverse diameter of lesion (LDi); absence of non-measured lesion; organ enlargement regressed to normal; no new lesions; normal bone marrow morphology; if indeterminate, immunohistochemistry negative.
Time frame: From the date of randomization until disease progression or death or study cut-off date, whichever comes first (maximum duration: up to 103 weeks)
Cohort A2, B and C: Percentage of Participants With Objective Response (OR)
Percentage of participants who had a CR or partial response (PR) as BOR using LRC, 2014. Per LRC, CR (PET-CT): complete MR in lymph nodes and extralymphatic sites with a score of 1, 2, or 3 with or without residual mass; no new lesions and no evidence of FDG-avid disease. CR (CT-response): target nodes/nodal masses of lymph nodes, extralymphatic sites regressed to \<=1.5cm LDi; absence of non-measured lesion; organ enlargement regressed to normal; no new lesions; normal bone marrow morphology. PR (PET-CT): partial MR in lymph nodes and extralymphatic sites; no new lesions and residual uptake higher than uptake. PR (Per CT): lymph nodes, extralymphatic sites\>=50% decrease in sum of product of perpendicular diameters (SPD), extranodal sites; if lesion is too small to measure on CT,assign5mm\*5mm as default; if no longer visible:0\*0mm; Node\>5mm\*5mm but smaller than normal, use actual measurement; absent/regressed non-measured lesions; no increase; spleen regressed by\>50% or no new lesions.
Time frame: From the date of randomization until disease progression, or death or study cut-off date, whichever comes first (maximum duration: up to 103 weeks)
Number of Participants With Treatment-Induced and Treatment Boosted Antidrug Antibodies (ADA) Against Isatuximab
ADA responses were categorized as treatment boosted ADA and treatment-induced ADA. Treatment boosted ADA was defined as pre-existing ADAs with a significant increase in the ADA titer during the study compared to the Baseline titer. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA.
Time frame: From first dose of study treatment up to 30 days after last dose of study treatment (maximum duration: up to 103 weeks)
Number of Participants With Treatment-Induced and Treatment Boosted Antidrug Antibodies (ADA) Against Cemiplimab
ADA responses were categorized as treatment boosted ADA and treatment-induced ADA. Treatment boosted ADA was defined as pre-existing ADAs with a significant increase in the ADA titer during the study compared to the Baseline titer. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA.
Time frame: From first dose of study treatment up to 30 days after last dose of study treatment (maximum duration: up to 103 weeks)
Pharmacokinetics (PK) Parameter: Plasma Concentration of Isatuximab at End of Infusion (CEOI)
Ceoi is the plasma concentration observed at the end of intravenous infusion of isatuximab.
Time frame: End of infusion (EOI up to 3 hours) on Day 2 of Cycle 1
PK Parameter: Maximum Observed Plasma Concentration (Cmax) After the First Infusion of Isatuximab
Cmax was defined as the maximum plasma concentration observed after the first administration of drug.
Time frame: At Start of infusion (SOI; 0 hour), before actual EOI (up to 3 hours), EOI+ 4 hours, 72 hours and 144 hours post-dose on Day 2 of Cycle 1
PK Parameter: Time to Reach Cmax (Tmax) After the First Infusion of Isatuximab
Tmax was defined as the time to reach Cmax, after the intravenous infusion of isatuximab.
Time frame: At SOI (0 hour), before actual EOI (up to 3 hours), EOI+ 4 hours, 72 hours and 144 hours post-dose on Day 2 of Cycle 1
PK Parameter: Area Under the Plasma Concentration (AUClast) Versus Time Curve After the First Infusion of Isatuximab
AUClast was defined as area under the plasma concentration versus time curve calculated from time 0 to last quantifiable concentration, calculated for isatuximab.
Time frame: At SOI (0 hour), before actual EOI (up to 3 hours), EOI+ 4 hours, 72 hours and 144 hours post-dose on Day 2 of Cycle 1
PK Parameter: Last Concentration Observed Above the Lower Limit of Quantification (Clast) After the First Infusion of Isatuximab
Clast was defined as the last concentration of isatuximab observed above the lower limit of quantification.
Time frame: At SOI (0 hour), before actual EOI (up to 3 hours), EOI+ 4 hours, 72 hours and 144 hours post-dose on Day 2 of Cycle 1
PK Parameter: Time of Clast (Tlast) After the First Infusion of Isatuximab
Tlast was defined as the time of last concentration observed above the lower limit of quantification for isatuximab.
Time frame: At SOI (0 hour), before actual EOI (up to 3 hours), EOI+ 4 hours, 72 hours and 144 hours post-dose on Day 2 of Cycle 1
PK Parameter: Area Under the Concentration Versus Time Curve Over the Dosing Interval (AUC0-168 Hours) After the First Infusion of Isatuximab
AUC0-168 hours was defined as the area under the plasma concentration versus time curve from time 0 to 168 hours post dose calculated for isatuximab. Samples for this outcome measure were collected up to 144 hours post-dose. No sample was collected at 168 hours post-dose; and thus, the samples collected up to 144 hours post-dose were extrapolated to derive data for 168 hours post-dose.
Time frame: At SOI (0 hour), before actual EOI (up to 3 hours), EOI+ 4 hours, 72 hours and 144 hours post-dose on Day 2 of Cycle 1
PK Parameter: Area Under the Concentration Versus Time Curve Over the Dosing Interval (AUC0-144 Hours) After the First Infusion of Isatuximab
AUC0-144 hours was defined as the area under the plasma concentration versus time curve from time 0 to 144 hours post dose calculated for isatuximab.
Time frame: At SOI (0 hour), before actual EOI (up to 3 hours), EOI+ 4 hours, 72 hours and 144 hours post-dose on Day 2 of Cycle 1
PK Parameter: Plasma Trough Concentration (Ctrough) of Isatuximab
Ctrough was the plasma concentration of isatuximab observed just before treatment administration during repeated dosing.
Time frame: Pre-infusion on Cycle1:Day 2, 8, 15, & 22, Cycle 2:Day 1 &15, Cycle 3:Day 1 &15, Cycle 4:Day 1 &15, Cycle 5 Day1,Cycle 6 Day1,Cycle 7 Day 1, Cycle 8 Day1, Cycle 9 Day1, Cycle 10 Day1, Cycle 11 Day1, Cycle14 Day1, Cycle 17 Day1, Cycle 20 Day1,Cycle 23 Day1
PK Parameter: Serum Concentration of Cemiplimab at End of Infusion (CEOI)
Ceoi is the plasma concentration observed at the end of intravenous infusion of cemiplimab.
Time frame: EOI (up to 30 minutes [min]) on Day 1 of Cycle 1
PK Parameter: Maximum Observed Concentration (Cmax) After the First Infusion of Cemiplimab
Cmax was defined as the maximum concentration observed after the first administration.
Time frame: At SOI (0 hour), before actual EOI (up to 30 min), EOI+4 hours, 96 hours, 168 hours, and 336 hours post-dose on Day 1 of Cycle 1
PK Parameter: Time to Reach Cmax (Tmax) After the First Infusion of Cemiplimab
Tmax was defined as the time to reach Cmax after the intravenous infusion of cemiplimab.
Time frame: At SOI (0 hour), before actual EOI (up to 30 min), EOI+4 hours, 96 hours, 168 hours, and 336 hours post-dose on Day 1 of Cycle 1
PK Parameter: Area Under the Serum Concentration (AUClast) Versus Time Curve After the First Infusion of Cemiplimab
AUClast was defined as area under the serum concentration versus time curve calculated from time 0 to last quantifiable concentration calculated for cemiplimab.
Time frame: At SOI (0 hour), before actual EOI (up to 30 min), EOI+4 hours, 96 hours, 168 hours, and 336 hours post-dose on Day 1 of Cycle 1
PK Parameter: Last Concentration Observed Above the Lower Limit of Quantification (Clast) After the First Infusion of Cemiplimab
Clast was defined as the last concentration of cemiplimab observed above the lower limit of quantification.
Time frame: At SOI (0 hour), before actual EOI (up to 30 min), EOI+4 hours, 96 hours, 168 hours, and 336 hours post-dose on Day 1 of Cycle 1
PK Parameter: Time of Clast (Tlast) After the First Infusion of Cemiplimab
Tlast was defined as the time of last concentration observed above the lower limit of quantification for cemiplimab.
Time frame: At SOI (0 hour), before actual EOI (up to 30 min), EOI+4 hours, 96 hours, 168 hours, and 336 hours post-dose on Day 1 of Cycle 1
PK Parameter: Area Under the Serum Concentration Versus Time Curve Over the Dosing Interval (AUC0-336 Hours) After the First Infusion of Cemiplimab
AUC0-336 hours was defined as the area under the serum concentration versus time curve from time 0 to 336 hours post dose for cemiplimab.
Time frame: At SOI (0 hour), before actual EOI (up to 30 min), EOI+4 hours, 96 hours, 168 hours, and 336 hours post-dose on Day 1 of Cycle 1
PK Parameter: Serum Trough Concentration (Ctrough) of Cemiplimab
Ctrough was the serum concentration of cemiplimab observed just before treatment administration during repeated dosing.
Time frame: Pre-infusion on Cycle 1:Day 1 & Day15,Cycle 2:Day 1 & Day 15,Cycle 3:Day 1 & Day 15,Cycle 4:Day 1 & Day15,Cycle 5 Day 1,Cycle 6 Day 1,Cycle7 Day1,Cycle 8 Day 1,Cycle 9 Day1,Cycle 10 Day1,Cycle11 Day1,Cycle14 Day 1,Cycle 17 Day1,Cycle20 Day 1,Cycle 23 Day1
Percent Change From Baseline in Tumor Burden
Tumor burden change was defined as the best percent-change from baseline in a sum of product of lesion diameters (longest for non-nodal lesion, short axis for nodal lesions) for all target lesions.
Time frame: Up to 103 weeks
Duration of Response (DOR)
Time (months) between date of first response to first date that recurrent or radiologically disease progression (PD) was documented, or date of death,whichever was 1st. In absence of PD or death before cut-off date or date of initiation of further anticancer treatment, DOR was censored at date of last valid response not showing PD performed prior to initiation of further anticancer treatment or cut-off date, whichever was earlier. PD(PET-CT): metabolic disease with score 4/5 with inc. in intensity of uptake for target nodes/nodal mass \& new FDG-avid foci consistent with lymphoma. PD(CT):any 1 of following: cross product of longest transverse diameter of lesion(LDi) \& perpendicular diameter (PPD) progression of nodes/nodal mass, abnormal node/lesion with LDi \>1.5 cm, inc \>=50% from PPD nadir \& inc in LDi/ shortest axis perpendicular to LDi(SDi) from nadir 0.5 cm, regrowth of resolved lesions, new splenomegaly,progression of non-measured lesion, new/recurrent involvement of bone marrow.
Time frame: From the date of first response until disease progression or death, or study cut-off date whichever occurred first (maximum duration: up to 103 weeks)
Percentage of Participants With Disease Control (DC)
DC defined as percentage of participants who achieved CR, PR or stable disease (SD) as per LRC, 2014. CR (PET-CT): complete MR in lymph nodes and extralymphatic sites; no new lesions and no evidence of FDG-avid disease. CR (CT): target nodes/nodal masses of lymph nodes, extralymphatic sites regressed to \<=1.5cm LDi; absence of non-measured lesion; organ enlargement regressed to normal; no new lesions; normal bone marrow. PR (PET-CT): partial MR in lymph nodes and sites; no new lesions. PR (CT): lymph nodes, sites\>=50% decrease in SPD, sites; if lesion is too small to measure on CT, assign 5mm\*5mm; No longer visible:0\*0mm; Node\>5mm\*5mm, use actual measurement; absent/regressed non-measured lesions; no increase; spleen regressed by\>50% or no new lesions. SD (PET-CT):no metabolic response, target nodes score of 4/5 with no significant change \& no new lesions; SD (CT): \<50% dec in SPD, no increase in progression for. 5PS:1: non-measured lesions, organ enlargement \& no new lesions.
Time frame: From the date of first response until disease progression or death, or study cut-off date whichever occurred first (maximum duration: up to 103 weeks)
Progression Free Survival (PFS)
PFS: time (in months) from 1st study treatment administration to date of 1st documented radiographic progression or date of death from any cause, whichever occurs 1st. Per LRC, 2014 PD (per PET-CT): metabolic disease with score 4/5 with increase (inc) in intensity of uptake for individual target nodes/nodal mass \& new FDG-avid foci consistent with lymphoma at interim/ end-of-treatment assessment for extra nodal lesions, new FDG-avid foci consistent with lymphoma rather; new/recurrent FDG-avid foci bone marrow. PD (per CT response): any 1 of following: cross product of longest transverse diameter of lesion (LDi) \& perpendicular diameter (PPD) progression of nodes/nodal mass, abnormal node/lesion with LDi \>1.5 cm, inc \>=50% from PPD nadir \& inc in LDi/ shortest axis perpendicular to LDi from nadir 0.5 cm for lesion \<= 2 cm, regrowth of resolved lesions, new splenomegaly,progression of preexisting non measured lesion, new/recurrent involvement of bone marrow.
Time frame: From the date of randomization until disease progression, or death or study cut-off date, whichever comes first (maximum duration: up to 103 weeks)
Cohort A1 and A2: Percentage of Participants With Objective Response
Percentage of participants who had a CR or PR as BOR using LRC, 2014 (based on PET-CT and CT responses). CR (per PET-CT): complete MR in lymph nodes and extra lymphatic sites with a score of 1, 2, or 3 with or without residual mass; no new lesions and no evidence of FDG-avid disease. CR (CT-response): target nodes/nodal masses of lymph nodes, extralymphatic sites regressed to \<=1.5cm LDi; absence of non-measured lesion; organ enlargement regressed to normal; no new lesions; normal bone marrow morphology. PR (per PET-CT): partial MR in lymph nodes and extral ymphatic sites; no new lesions and residual uptake higher than uptake. PR (per CT): lymph nodes, extralymphatic sites \>=50% decrease in SPD, extranodal sites; if lesion is too small to measure on CT, assign 5mm\*5mm as default; if no longer visible:0\*0mm; Node\>5mm\*5mm but smaller than normal, used actual measurement; absent/regressed non-measured lesions; no increase; spleen regressed by\>50% or no new lesions.
Time frame: From the date of randomization until disease progression, or death or study cut-off date, whichever comes first (maximum duration: up to 103 weeks)
Cohort A1 and A2: Percentage of Participants With Complete Response
Percentage of participants who had a CR as a BOR using the LRC, 2014 (based on PET-CT and CT responses). Per LRC, CR based on PET-CT was defined as complete MR in lymph nodes and extralymphatic sites with a score of 1, 2, or 3 with or without residual mass, on 5PS, where, 1= no uptake above background; 2 = uptake \<=mediastinum; 3 = uptake \> mediastinum but \<= liver; 4 = uptake moderately \> liver; 5 = uptake markedly higher than liver and/or new lesions; no new lesions and no evidence of FDG-avid disease in bone marrow. CR based on CT-response was defined as target nodes/nodal masses of lymph nodes, extralymphatic sites regressed to \<=1.5 cm in longest dimension transverse diameter of lesion (LDi); absence of non-measured lesion; organ enlargement regressed to normal; no new lesions; normal bone marrow morphology; if indeterminate, immunohistochemistry negative.
Time frame: From the date of randomization until disease progression, or death or study cut-off date, whichever comes first (maximum duration: up to 103 weeks)
Study was conducted at 20 sites in 7 countries. A total of 58 participants were enrolled between 11 December 2018 and 27 August 2020 and received isatuximab in combination with cemiplimab. Study was planned to be conducted in 2 parts: Phase 1(safety run-in) and Phase 2 (efficacy/2-stage design).
| Milestone | Cohort A1: cHL: Isatuximab + Cemiplimab | Cohort A2: cHL: Isatuximab + Cemiplimab | Cohort B: DLBCL: Isatuximab + Cemiplimab | Cohort C: PTCL: Isatuximab + Cemiplimab |
|---|---|---|---|---|
| Started | 18 | 12 | 17 | 11 |
| Completed | 5 | 4 | 0 | 0 |
| Not completed | 13 | 8 | 17 | 11 |
| Withdrew: Adverse event | 1 | 0 | 2 | 4 |
| Withdrew: Withdrawal by subject | 1 | 0 | 2 | 1 |
| Withdrew: Progressive disease | 9 | 7 | 13 | 6 |
| Withdrew: Other - unspecified | 2 | 1 | 0 | 0 |
DLTs: Adverse Events (AEs) occurring during 1st treatment cycle, unless due to disease progression or obviously unrelated cause which included: hematological abnormalities: Grade(G) 4 neutropenia(N) for 7 or more consecutive days, G3 to G4 N with fever (temperature greater than or equal to \[\>=\] 38.5 degree Celsius on more than 1 occasion) or microbiologically/radiographically documented infection, G3 to G4 thrombocytopenia with clinically significant bleeding requiring clinical intervention or non-hematological abnormalities: G 4 non-hematologic AE, G\>=2 uveitis, G3 non-hematological AE lasting greater than (\>)3 days, delay in initiation of Cycle 2 \>14 days due to treatment related laboratory abnormalities/AE. Any other AE that the study committee deemed to be dose-limiting, regardless of grade, was also considered as DLT.
| Participants | Cohort A1: cHL: Isatuximab + Cemiplimab | Cohort A2: cHL: Isatuximab + Cemiplimab | Cohort B: DLBCL: Isatuximab + Cemiplimab | Cohort C: PTCL: Isatuximab + Cemiplimab |
|---|---|---|---|---|
| Number of Participants With Dose Limiting Toxicities (DLTs) | — | 0 | 0 | 0 |
An AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. Serious adverse events (SAEs) were any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as AEs that developed, worsened or became serious during the TEAE period (defined as the time from the first dose of study treatment up to 30 days after the last dose of study treatment).
| Participants | Cohort A1: cHL: Isatuximab + Cemiplimab | Cohort A2: cHL: Isatuximab + Cemiplimab | Cohort B: DLBCL: Isatuximab + Cemiplimab | Cohort C: PTCL: Isatuximab + Cemiplimab |
|---|---|---|---|---|
| TEAEs | 16 | 12 | 17 | 11 |
| TESAEs | 3 | 2 | 10 | 7 |
Hematological parameters assessed were anemia, white blood cell (WBC) decreased, platelet count decreased, lymphocyte count decreased, and neutrophil count decreased. Abnormality criteria was assessed as per the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 NCI-CTCAE v 5.0), where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs.
| Participants | Cohort A1: cHL: Isatuximab + Cemiplimab | Cohort A2: cHL: Isatuximab + Cemiplimab | Cohort B: DLBCL: Isatuximab + Cemiplimab | Cohort C: PTCL: Isatuximab + Cemiplimab |
|---|---|---|---|---|
| Anemia: Grade 1 | 9 | 6 | 7 | 6 |
| Anemia: Grade 2 | 5 | 1 | 7 | 3 |
| Anemia: Grade 3 | 2 | 0 | 2 | 2 |
| Anemia: Grade 4 | 0 | 0 | 0 | 0 |
| White blood cell decreased: Grade 1 | 10 | 2 | 9 | 3 |
| White blood cell decreased: Grade 2 | 1 | 1 | 2 | 4 |
| White blood cell decreased: Grade 3 | 0 | 0 | 1 | 2 |
| White blood cell decreased: Grade 4 | 0 | 0 | 2 | 0 |
| Platelet count decreased: Grade 1 | 8 | 3 | 7 | 3 |
| Platelet count decreased: Grade 2 | 0 | 0 | 2 | 1 |
| Platelet count decreased: Grade 3 | 0 | 0 | 0 | 1 |
| Platelet count decreased: Grade 4 | 0 | 0 | 2 | 3 |
| Lymphocyte count decreased: Grade 1 | 4 | 2 | 2 | 0 |
| Lymphocyte count decreased: Grade 2 | 3 | 0 | 4 | 6 |
| Lymphocyte count decreased: Grade 3 | 5 | 1 | 6 | 3 |
| Lymphocyte count decreased: Grade 4 | 1 | 0 | 2 | 1 |
| Neutrophil count decreased: Grade 1 | 0 | 0 | 2 | 2 |
| Neutrophil count decreased: Grade 2 | 3 | 0 | 2 | 2 |
| Neutrophil count decreased: Grade 3 | 0 | 0 | 1 | 1 |
| Neutrophil count decreased: Grade 4 | 0 | 0 | 2 | 2 |
Electrolyte parameters assessed were hyponatremia, hypokalemia, hyperkalemia, hypocalcemia, hypercalcemia, hypoalbuminemia, hypoglycemia and hyperglycemia. Abnormal criteria was assessed as per the NCI-CTCAE v 5.0, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs.
| Participants | Cohort A1: cHL: Isatuximab + Cemiplimab | Cohort A2: cHL: Isatuximab + Cemiplimab | Cohort B: DLBCL: Isatuximab + Cemiplimab | Cohort C: PTCL: Isatuximab + Cemiplimab |
|---|---|---|---|---|
| Hyponatremia: Grade 1 | 8 | 4 | 6 | 5 |
| Hyponatremia: Grade 2 | 0 | 0 | 0 | 0 |
| Hyponatremia: Grade 3 | 0 | 0 | 2 | 3 |
| Hyponatremia: Grade 4 | 0 | 0 | 0 | 0 |
| Hypokalemia: Grade 1 | 0 | 0 | 0 | 0 |
| Hypokalemia: Grade 2 | 3 | 3 | 3 | 5 |
| Hypokalemia: Grade 3 | 0 | 0 | 3 | 0 |
| Hypokalemia: Grade 4 | 0 | 0 | 0 | 0 |
| Hyperkalemia: Grade 1 | 1 | 2 | 2 | 1 |
| Hyperkalemia: Grade 2 | 1 | 0 | 0 | 1 |
| Hyperkalemia: Grade 3 | 0 | 0 | 0 | 1 |
| Hyperkalemia: Grade 4 | 0 | 0 | 0 | 0 |
| Hypocalcemia: Grade 1 | 1 | 0 | 1 | 1 |
| Hypocalcemia: Grade 2 | 0 | 0 | 0 | 0 |
| Hypocalcemia: Grade 3 | 0 | 0 | 0 | 0 |
| Hypocalcemia: Grade 4 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia: Grade 1 | 3 | 2 | 5 | 2 |
| Hypoalbuminemia: Grade 2 | 4 | 0 | 6 | 5 |
| Hypoalbuminemia: Grade 3 | 0 | 0 | 0 | 1 |
| Hypoalbuminemia: Grade 4 | 0 | 0 | 0 | 0 |
| Hypoglycemia: Grade 1 | 5 | 1 | 0 | 1 |
| Hypoglycemia: Grade 2 | 0 | 0 | 0 | 1 |
| Hypoglycemia: Grade 3 | 0 | 0 | 0 | 0 |
| Hypoglycemia: Grade 4 | 0 | 0 | 0 | 0 |
| Hyperglycemia: Grade 1 | 2 | 5 | 1 | 6 |
| Hyperglycemia: Grade 2 | 2 | 2 | 3 | 2 |
| Hyperglycemia: Grade 3 | 2 | 0 | 1 | 0 |
| Hyperglycemia: Grade 4 | 0 | 0 | 0 | 0 |
| Hypercalcemia: Grade 1 | 0 | 0 | 0 | 0 |
| Hypercalcemia: Grade 2 | 0 | 0 | 0 | 0 |
| Hypercalcemia: Grade 3 | 0 | 0 | 1 | 0 |
| Hypercalcemia: Grade 4 | 0 | 0 | 0 | 0 |
Abnormal renal parameters assessed were glomerular filtration rate (GFR) by class, creatinine increased and hyperuricemia. GFR by class was assessed in categories:\>=90 milliliter per minute per 1.73 meter square (mL/min/1.73m\^2) (Normal), \>=60 to \<90 mL/min/1.73m\^2 (Mild), \>=30 to \<60 mL/min/1.73m\^2 (Moderate), \>=15 to \<30 mL/min/1.73m\^2 (Severe), and \<15 mL/min/1.73m\^2 (End Stage Renal Disease). Abnormal criteria was assessed as per NCI-CTCAE v 5.0, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs.
| Participants | Cohort A1: cHL: Isatuximab + Cemiplimab | Cohort A2: cHL: Isatuximab + Cemiplimab | Cohort B: DLBCL: Isatuximab + Cemiplimab | Cohort C: PTCL: Isatuximab + Cemiplimab |
|---|---|---|---|---|
| GFR: >=90 mL/min/1.73m^2 | 7 | 2 | 4 | 1 |
| GFR: >=60 to <90 mL/min/1.73m^2 | 8 | 8 | 8 | 7 |
| GFR: >=30 to <60 mL/min/1.73m^2 | 3 | 2 | 4 | 2 |
| GFR: >=15 to <30 mL/min/1.73m^2 | 0 | 0 | 1 | 1 |
| GFR: <15 mL/min/1.73m^2 | 0 | 0 | 0 | 0 |
| Creatinine increased: Grade 1 | 2 | 3 | 4 | 1 |
| Creatinine increased: Grade 2 | 3 | 1 | 3 | 4 |
| Creatinine increased: Grade 3 | 0 | 0 | 0 | 0 |
| Creatinine increased: Garde 4 | 0 | 0 | 0 | 0 |
| Hyperuricemia: Grade 1 | 0 | 0 | 0 | 0 |
| Hyperuricemia: Grade 2 | 0 | 0 | 0 | 0 |
| Hyperuricemia: Grade 3 | 1 | 3 | 5 | 2 |
| Hyperuricemia: Grade 4 | 0 | 0 | 0 | 0 |
Abnormal liver function parameters assessed were aspartate aminotransferase (AST) increased, alanine aminotransferase (ALT) increased, alkaline phosphatase (ALP) increased, blood bilirubin (BB) increased. Abnormal criteria was assessed as per NCI-CTCAE v 5.0, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs.
| Participants | Cohort A1: cHL: Isatuximab + Cemiplimab | Cohort A2: cHL: Isatuximab + Cemiplimab | Cohort B: DLBCL: Isatuximab + Cemiplimab | Cohort C: PTCL: Isatuximab + Cemiplimab |
|---|---|---|---|---|
| AST increased: Grade 1 | 3 | 2 | 5 | 3 |
| AST increased: Grade 2 | 0 | 0 | 1 | 0 |
| AST increased: Grade 3 | 0 | 0 | 0 | 0 |
| AST increased: Grade 4 | 0 | 0 | 0 | 0 |
| ALT increased: Grade 1 | 1 | 7 | 6 | 0 |
| ALT increased: Grade 2 | 0 | 0 | 0 | 0 |
| ALT increased: Grade 3 | 0 | 0 | 0 | 0 |
| ALT increased: Grade 4 | 0 | 0 | 0 | 0 |
| ALP increased: Grade 1 | 3 | 5 | 4 | 5 |
| ALP increased: Grade 2 | 2 | 0 | 2 | 0 |
| ALP increased: Grade 3 | 0 | 0 | 0 | 0 |
| ALP increased: Grade 4 | 0 | 0 | 0 | 0 |
| BB increased: Grade 1 | 1 | 0 | 1 | 2 |
| BB increased: Grade 2 | 0 | 0 | 2 | 1 |
| BB increased: Grade 3 | 0 | 0 | 1 | 0 |
| BB increased: Grade 4 | 0 | 0 | 0 | 0 |
Percentage of participants who had a CR as a best overall response (BOR) using the Lugano response criteria (LRC) 2014 (based on PET-CT and CT responses). Per LRC, CR based on PET-CT response was defined as complete metabolic response (MR) in lymph nodes and extralymphatic sites with a score of 1, 2, or 3 with or without residual mass, on 5-point scale (5PS), where, 1= no uptake above background; 2 = uptake \<=mediastinum; 3 = uptake \> mediastinum but \<= liver; 4 = uptake moderately \> liver; 5 = uptake markedly higher than liver and/or new lesions; no new lesions and no evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow. CR based on CT-response was defined as target nodes/nodal masses of lymph nodes, extralymphatic sites regressed to \<=1.5 cm in longest dimension transverse diameter of lesion (LDi); absence of non-measured lesion; organ enlargement regressed to normal; no new lesions; normal bone marrow morphology; if indeterminate, immunohistochemistry negative.
| percentage of participants | Cohort A1: cHL: Isatuximab + Cemiplimab |
|---|---|
| Cohort A1: Percentage of Participants With Complete Response (CR) | 27.8 |
Percentage of participants who had a CR or partial response (PR) as BOR using LRC, 2014. Per LRC, CR (PET-CT): complete MR in lymph nodes and extralymphatic sites with a score of 1, 2, or 3 with or without residual mass; no new lesions and no evidence of FDG-avid disease. CR (CT-response): target nodes/nodal masses of lymph nodes, extralymphatic sites regressed to \<=1.5cm LDi; absence of non-measured lesion; organ enlargement regressed to normal; no new lesions; normal bone marrow morphology. PR (PET-CT): partial MR in lymph nodes and extralymphatic sites; no new lesions and residual uptake higher than uptake. PR (Per CT): lymph nodes, extralymphatic sites\>=50% decrease in sum of product of perpendicular diameters (SPD), extranodal sites; if lesion is too small to measure on CT,assign5mm\*5mm as default; if no longer visible:0\*0mm; Node\>5mm\*5mm but smaller than normal, use actual measurement; absent/regressed non-measured lesions; no increase; spleen regressed by\>50% or no new lesions.
| percentage of participants | Cohort A2: cHL: Isatuximab + Cemiplimab | Cohort B: DLBCL: Isatuximab + Cemiplimab | Cohort C: PTCL: Isatuximab + Cemiplimab |
|---|---|---|---|
| Cohort A2, B and C: Percentage of Participants With Objective Response (OR) | 33.3 (12.3 to 60.9) | 5.9 (0.3 to 25.0) | 9.1 (0.5 to 36.4) |
ADA responses were categorized as treatment boosted ADA and treatment-induced ADA. Treatment boosted ADA was defined as pre-existing ADAs with a significant increase in the ADA titer during the study compared to the Baseline titer. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA.
| Participants | Cohort A1: cHL: Isatuximab + Cemiplimab | Cohort A2: cHL: Isatuximab + Cemiplimab | Cohort B: DLBCL: Isatuximab + Cemiplimab | Cohort C: PTCL: Isatuximab + Cemiplimab |
|---|---|---|---|---|
| Treatment-Induced ADA | 1 | 0 | 0 | 0 |
| Treatment-Boosted ADA | 0 | 0 | 0 | 0 |
ADA responses were categorized as treatment boosted ADA and treatment-induced ADA. Treatment boosted ADA was defined as pre-existing ADAs with a significant increase in the ADA titer during the study compared to the Baseline titer. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA.
| Participants | Cohort A1: cHL: Isatuximab + Cemiplimab | Cohort A2: cHL: Isatuximab + Cemiplimab | Cohort B: DLBCL: Isatuximab + Cemiplimab | Cohort C: PTCL: Isatuximab + Cemiplimab |
|---|---|---|---|---|
| Treatment-Induced ADA | 0 | 0 | 1 | 0 |
| Treatment-Boosted ADA | 0 | 0 | 0 | 0 |
Ceoi is the plasma concentration observed at the end of intravenous infusion of isatuximab.
| micrograms per milliliter (mcg/mL) | Cohort A1: cHL: Isatuximab | Cohort A2: cHL: Isatuximab | Cohort B: DLBCL: Isatuximab | Cohort C: PTCL: Isatuximab |
|---|---|---|---|---|
| Pharmacokinetics (PK) Parameter: Plasma Concentration of Isatuximab at End of Infusion (CEOI) | 221 ± 47.2 | 263 ± 39.4 | 235 ± 39.3 | 181 ± 35.7 |
Cmax was defined as the maximum plasma concentration observed after the first administration of drug.
| mcg/mL | Cohort A1: cHL: Isatuximab | Cohort A2: cHL: Isatuximab | Cohort B: DLBCL: Isatuximab | Cohort C: PTCL: Isatuximab |
|---|---|---|---|---|
| PK Parameter: Maximum Observed Plasma Concentration (Cmax) After the First Infusion of Isatuximab | 226 ± 48.1 | 265 ± 38.8 | 253 ± 29.1 | 181 ± 35.7 |
Tmax was defined as the time to reach Cmax, after the intravenous infusion of isatuximab.
| hours | Cohort A1: cHL: Isatuximab | Cohort A2: cHL: Isatuximab | Cohort B: DLBCL: Isatuximab | Cohort C: PTCL: Isatuximab |
|---|---|---|---|---|
| PK Parameter: Time to Reach Cmax (Tmax) After the First Infusion of Isatuximab | 5.95 (2.00 to 8.92) | 5.23 (3.00 to 8.83) | 5.26 (2.60 to 10.5) | 4.57 (2.33 to 7.45) |
AUClast was defined as area under the plasma concentration versus time curve calculated from time 0 to last quantifiable concentration, calculated for isatuximab.
| hours*mcg/mL | Cohort A1: cHL: Isatuximab | Cohort A2: cHL: Isatuximab | Cohort B: DLBCL: Isatuximab | Cohort C: PTCL: Isatuximab |
|---|---|---|---|---|
| PK Parameter: Area Under the Plasma Concentration (AUClast) Versus Time Curve After the First Infusion of Isatuximab | 20400 ± 5190 | 22700 ± 6020 | 21700 ± 4610 | 14400 ± 4710 |
Clast was defined as the last concentration of isatuximab observed above the lower limit of quantification.
| mcg/mL | Cohort A1: cHL: Isatuximab | Cohort A2: cHL: Isatuximab | Cohort B: DLBCL: Isatuximab | Cohort C: PTCL: Isatuximab |
|---|---|---|---|---|
| PK Parameter: Last Concentration Observed Above the Lower Limit of Quantification (Clast) After the First Infusion of Isatuximab | 93.3 ± 28.1 | 110 ± 24.5 | 89.8 ± 24.7 | 40.4 ± 17.7 |
Tlast was defined as the time of last concentration observed above the lower limit of quantification for isatuximab.
| hours | Cohort A1: cHL: Isatuximab | Cohort A2: cHL: Isatuximab | Cohort B: DLBCL: Isatuximab | Cohort C: PTCL: Isatuximab |
|---|---|---|---|---|
| PK Parameter: Time of Clast (Tlast) After the First Infusion of Isatuximab | 142 (136 to 174) | 143 (72.6 to 167) | 143 (137 to 147) | 144 (142 to 169) |
AUC0-168 hours was defined as the area under the plasma concentration versus time curve from time 0 to 168 hours post dose calculated for isatuximab. Samples for this outcome measure were collected up to 144 hours post-dose. No sample was collected at 168 hours post-dose; and thus, the samples collected up to 144 hours post-dose were extrapolated to derive data for 168 hours post-dose.
| hour*mcg/mL | Cohort A1: cHL: Isatuximab | Cohort A2: cHL: Isatuximab | Cohort B: DLBCL: Isatuximab | Cohort C: PTCL: Isatuximab |
|---|---|---|---|---|
| PK Parameter: Area Under the Concentration Versus Time Curve Over the Dosing Interval (AUC0-168 Hours) After the First Infusion of Isatuximab | 22500 ± 5770 | 26600 ± 4030 | 23700 ± 4960 | 15000 ± 4680 |
AUC0-144 hours was defined as the area under the plasma concentration versus time curve from time 0 to 144 hours post dose calculated for isatuximab.
| hours*mcg/mL | Cohort A1: cHL: Isatuximab | Cohort A2: cHL: Isatuximab | Cohort B: DLBCL: Isatuximab | Cohort C: PTCL: Isatuximab |
|---|---|---|---|---|
| PK Parameter: Area Under the Concentration Versus Time Curve Over the Dosing Interval (AUC0-144 Hours) After the First Infusion of Isatuximab | 20400 ± 5170 | 24300 ± 3470 | 21800 ± 4550 | 14000 ± 4240 |
Ctrough was the plasma concentration of isatuximab observed just before treatment administration during repeated dosing.
| mcg/mL | Cohort A1: cHL: Isatuximab | Cohort A2: cHL: Isatuximab | Cohort B: DLBCL: Isatuximab | Cohort C: PTCL: Isatuximab |
|---|---|---|---|---|
| Cycle 1 Day 2 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Cycle 1 Day 8 | 93.1 ± 28.1 | 98.4 ± 39.5 | 93.2 ± 27.2 | 37.7 ± 18.0 |
| Cycle 1 Day 15 | 159 ± 47.7 | 191 ± 41.4 | 181 ± 43.7 | 115 ± 89.4 |
| Cycle 1 Day 22 | 254 ± 59.8 | 262 ± 45.2 | 259 ± 57.9 | 124 ± 22.9 |
| Cycle 2 Day 1 | 310 ± 78.2 | 352 ± 48.7 | 316 ± 110 | 132 ± 64.0 |
| Cycle 2 Day 15 | 314 ± 141 | 390 ± 256 | 291 ± 108 | 129 ± 59.1 |
| Cycle 3 Day 1 | 304 ± 79.8 | 320 ± 49.7 | 327 ± 92.4 | 122 ± 58.0 |
| Cycle 3 Day 15 | 325 ± 85.1 | 336 ± 42.3 | 420 ± 67.8 | 176 ± 8.19 |
| Cycle 4 Day 1 | 334 ± 91.8 | 344 ± 58.2 | 350 ± 80.6 | 149 ± 33.2 |
| Cycle 4 Day 15 | 363 ± 122 | 376 ± 65.2 | 336 ± 117 | 158 ± 16.9 |
| Cycle 5 Day 1 | 385 ± 79.9 | 383 ± 71.0 | 362 | 157 ± 11.5 |
| Cycle 6 Day 1 | 379 ± 105 | 361 ± 97.8 | 415 | 137 |
| Cycle 7 Day 1 | 408 ± 141 | 374 ± 107 | — | 186 |
| Cycle 8 Day 1 | 352 ± 94.9 | 356 ± 57.7 | 360 | — |
| Cycle 9 Day 1 | 328 ± 124 | 351 ± 54.8 | — | 83.5 |
| Cycle 10 Day 1 | 317 ± 120 | 347 ± 51.8 | 383 | — |
| Cycle 11 Day 1 | 318 ± 147 | 357 ± 52.0 | — | — |
| Cycle 14 Day 1 | 357 ± 119 | 333 ± 28.0 | — | — |
| Cycle 17 Day 1 | — | 299 ± 22.3 | — | — |
| Cycle 20 Day 1 | 117 | 328 ± 14.4 | — | — |
| Cycle 23 Day 1 | — | 309 ± 9.90 | — | — |
Ceoi is the plasma concentration observed at the end of intravenous infusion of cemiplimab.
| milligrams per milliliter (mg/mL) | Cohort A1: cHL: Cemiplimab | Cohort A2: cHL: Cemiplimab | Cohort B: DLBCL: Cemiplimab | Cohort C: PTCL: Cemiplimab |
|---|---|---|---|---|
| PK Parameter: Serum Concentration of Cemiplimab at End of Infusion (CEOI) | 63.7 ± 24.2 | 78.8 ± 24.9 | 68.1 ± 26.3 | 66.2 ± 18.4 |
Cmax was defined as the maximum concentration observed after the first administration.
| mg/L | Cohort A1: cHL: Cemiplimab | Cohort A2: cHL: Cemiplimab | Cohort B: DLBCL: Cemiplimab | Cohort C: PTCL: Cemiplimab |
|---|---|---|---|---|
| PK Parameter: Maximum Observed Concentration (Cmax) After the First Infusion of Cemiplimab | 70.9 ± 21.1 | 90.8 ± 19.4 | 79.0 ± 16.7 | 77.1 ± 20.7 |
Tmax was defined as the time to reach Cmax after the intravenous infusion of cemiplimab.
| hours | Cohort A1: cHL: Cemiplimab | Cohort A2: cHL: Cemiplimab | Cohort B: DLBCL: Cemiplimab | Cohort C: PTCL: Cemiplimab |
|---|---|---|---|---|
| PK Parameter: Time to Reach Cmax (Tmax) After the First Infusion of Cemiplimab | 4.00 (0.480 to 4.67) | 4.50 (0.480 to 4.53) | 4.05 (0.420 to 5.40) | 2.34 (0.500 to 4.08) |
AUClast was defined as area under the serum concentration versus time curve calculated from time 0 to last quantifiable concentration calculated for cemiplimab.
| day*mg/mL | Cohort A1: cHL: Cemiplimab | Cohort A2: cHL: Cemiplimab | Cohort B: DLBCL: Cemiplimab | Cohort C: PTCL: Isatuximab + Cemiplimab |
|---|---|---|---|---|
| PK Parameter: Area Under the Serum Concentration (AUClast) Versus Time Curve After the First Infusion of Cemiplimab | 524 ± 188 | 648 ± 112 | 506 ± 159 | 466 ± 147 |
Clast was defined as the last concentration of cemiplimab observed above the lower limit of quantification.
| mg/L | Cohort A1: cHL: Cemiplimab | Cohort A2: cHL: Cemiplimab | Cohort B: DLBCL: Cemiplimab | Cohort C: PTCL: Cemiplimab |
|---|---|---|---|---|
| PK Parameter: Last Concentration Observed Above the Lower Limit of Quantification (Clast) After the First Infusion of Cemiplimab | 23.4 ± 11.2 | 30.3 ± 7.16 | 27.0 ± 9.79 | 14.3 ± 6.64 |
Tlast was defined as the time of last concentration observed above the lower limit of quantification for cemiplimab.
| hours | Cohort A1: cHL: Cemiplimab | Cohort A2: cHL: Cemiplimab | Cohort B: DLBCL: Cemiplimab | Cohort C: PTCL: Cemiplimab |
|---|---|---|---|---|
| PK Parameter: Time of Clast (Tlast) After the First Infusion of Cemiplimab | 334 (164 to 672) | 333 (330 to 362) | 332 (164 to 339) | 335 (171 to 572) |
AUC0-336 hours was defined as the area under the serum concentration versus time curve from time 0 to 336 hours post dose for cemiplimab.
| day*mg/mL | Cohort A1: cHL: Cemiplimab | Cohort A2: cHL: Cemiplimab | Cohort B: DLBCL: Cemiplimab | Cohort C: PTCL: Cemiplimab |
|---|---|---|---|---|
| PK Parameter: Area Under the Serum Concentration Versus Time Curve Over the Dosing Interval (AUC0-336 Hours) After the First Infusion of Cemiplimab | 519 ± 177 | 645 ± 113 | 546 ± 136 | 466 ± 130 |
Ctrough was the serum concentration of cemiplimab observed just before treatment administration during repeated dosing.
| mg/mL | Cohort A1: cHL: Cemiplimab | Cohort A2: cHL: Cemiplimab | Cohort B: DLBCL: Cemiplimab | Cohort C: PTCL: Cemiplimab |
|---|---|---|---|---|
| Cycle 1 Day 1 | 0.00800 ± 0.0330 | 0.980 ± 2.19 | 0 ± 0 | 0 ± 0 |
| Cycle 1 Day 15 | 25.3 ± 10.2 | 30.3 ± 7.16 | 24.2 ± 9.91 | 16.5 ± 4.83 |
| Cycle 2 Day 1 | 44.1 ± 11.2 | 51.1 ± 15.8 | 49.6 ± 16.3 | 33.0 ± 10.4 |
| Cycle 2 Day 15 | 64.4 ± 22.5 | 61.0 ± 10.8 | 48.9 ± 9.16 | 38.3 ± 21.1 |
| Cycle 3 Day 1 | 77.7 ± 30.2 | 73.7 ± 11.0 | 62.8 ± 13.6 | 66.7 ± 64.7 |
| Cycle 3 Day 15 | 95.1 ± 35.0 | 86.6 ± 19.5 | 72.3 ± 3.80 | 72.1 ± 12.1 |
| Cycle 4 Day 1 | 100 ± 38.9 | 84.4 ± 20.3 | 76.8 ± 4.31 | 66.7 ± 24.1 |
| Cycle 4 Day 15 | 113 ± 44.8 | 88.2 ± 30.5 | 91.6 ± 10.3 | 63.5 ± 24.8 |
| Cycle 5 Day 1 | 106 ± 28.9 | 92.7 ± 21.8 | 91.6 | 73.4 ± 26.5 |
| Cycle 6 Day 1 | 114 ± 37.3 | 94.8 ± 29.8 | 113 | 73.8 |
| Cycle 7 Day 1 | 112 ± 32.6 | 115 ± 43.0 | — | 100 |
| Cycle 8 Day 1 | 110 ± 40.5 | 129 ± 19.5 | 93.0 | — |
| Cycle 9 Day 1 | 107 ± 36.2 | 122 ± 27.9 | 122 | 61.8 |
| Cycle 10 Day 1 | 112 ± 65.8 | 139 ± 23.2 | 122 | — |
| Cycle 11 Day 1 | 120 ± 60.2 | 133 ± 14.5 | — | — |
| Cycle 14 Day 1 | 138 ± 72.7 | 127 ± 17.1 | — | — |
| Cycle 17 Day 1 | 60.6 | 131 ± 18.8 | — | — |
| Cycle 20 Day 1 | 62.6 | 137 ± 26.7 | — | — |
| Cycle 23 Day 1 | — | 137 | — | — |
Tumor burden change was defined as the best percent-change from baseline in a sum of product of lesion diameters (longest for non-nodal lesion, short axis for nodal lesions) for all target lesions.
| percent change | Cohort A1: cHL: Isatuximab + Cemiplimab | Cohort A2: cHL: Isatuximab + Cemiplimab | Cohort B: DLBCL: Isatuximab + Cemiplimab | Cohort C: PTCL: Isatuximab + Cemiplimab |
|---|---|---|---|---|
| Percent Change From Baseline in Tumor Burden | -48.8 ± 59.0 | -55.3 ± 32.6 | 396.0 ± 880.7 | -9.7 ± 87.8 |
Time (months) between date of first response to first date that recurrent or radiologically disease progression (PD) was documented, or date of death,whichever was 1st. In absence of PD or death before cut-off date or date of initiation of further anticancer treatment, DOR was censored at date of last valid response not showing PD performed prior to initiation of further anticancer treatment or cut-off date, whichever was earlier. PD(PET-CT): metabolic disease with score 4/5 with inc. in intensity of uptake for target nodes/nodal mass \& new FDG-avid foci consistent with lymphoma. PD(CT):any 1 of following: cross product of longest transverse diameter of lesion(LDi) \& perpendicular diameter (PPD) progression of nodes/nodal mass, abnormal node/lesion with LDi \>1.5 cm, inc \>=50% from PPD nadir \& inc in LDi/ shortest axis perpendicular to LDi(SDi) from nadir 0.5 cm, regrowth of resolved lesions, new splenomegaly,progression of non-measured lesion, new/recurrent involvement of bone marrow.
| months | Cohort A1: cHL: Isatuximab + Cemiplimab | Cohort A2: cHL: Isatuximab + Cemiplimab | Cohort B: DLBCL: Isatuximab + Cemiplimab | Cohort C: PTCL: Isatuximab + Cemiplimab |
|---|---|---|---|---|
| Duration of Response (DOR) | 5.8 ± 5.2 | 7.3 ± 4.8 | 17.1 | 14.0 |
DC defined as percentage of participants who achieved CR, PR or stable disease (SD) as per LRC, 2014. CR (PET-CT): complete MR in lymph nodes and extralymphatic sites; no new lesions and no evidence of FDG-avid disease. CR (CT): target nodes/nodal masses of lymph nodes, extralymphatic sites regressed to \<=1.5cm LDi; absence of non-measured lesion; organ enlargement regressed to normal; no new lesions; normal bone marrow. PR (PET-CT): partial MR in lymph nodes and sites; no new lesions. PR (CT): lymph nodes, sites\>=50% decrease in SPD, sites; if lesion is too small to measure on CT, assign 5mm\*5mm; No longer visible:0\*0mm; Node\>5mm\*5mm, use actual measurement; absent/regressed non-measured lesions; no increase; spleen regressed by\>50% or no new lesions. SD (PET-CT):no metabolic response, target nodes score of 4/5 with no significant change \& no new lesions; SD (CT): \<50% dec in SPD, no increase in progression for. 5PS:1: non-measured lesions, organ enlargement \& no new lesions.
| percentage of participants | Cohort A1: cHL: Isatuximab + Cemiplimab | Cohort A2: cHL: Isatuximab + Cemiplimab | Cohort B: DLBCL: Isatuximab + Cemiplimab | Cohort C: PTCL: Isatuximab + Cemiplimab |
|---|---|---|---|---|
| Percentage of Participants With Disease Control (DC) | 61.1 (39.2 to 80.1) | 58.3 (31.5 to 81.9) | 5.9 (0.3 to 25.0) | 18.2 (3.3 to 47.0) |
PFS: time (in months) from 1st study treatment administration to date of 1st documented radiographic progression or date of death from any cause, whichever occurs 1st. Per LRC, 2014 PD (per PET-CT): metabolic disease with score 4/5 with increase (inc) in intensity of uptake for individual target nodes/nodal mass \& new FDG-avid foci consistent with lymphoma at interim/ end-of-treatment assessment for extra nodal lesions, new FDG-avid foci consistent with lymphoma rather; new/recurrent FDG-avid foci bone marrow. PD (per CT response): any 1 of following: cross product of longest transverse diameter of lesion (LDi) \& perpendicular diameter (PPD) progression of nodes/nodal mass, abnormal node/lesion with LDi \>1.5 cm, inc \>=50% from PPD nadir \& inc in LDi/ shortest axis perpendicular to LDi from nadir 0.5 cm for lesion \<= 2 cm, regrowth of resolved lesions, new splenomegaly,progression of preexisting non measured lesion, new/recurrent involvement of bone marrow.
| months | Cohort A1: cHL: Isatuximab + Cemiplimab | Cohort A2: cHL: Isatuximab + Cemiplimab | Cohort B: DLBCL: Isatuximab + Cemiplimab | Cohort C: PTCL: Isatuximab + Cemiplimab |
|---|---|---|---|---|
| Progression Free Survival (PFS) | 5.09 (2.694 to 13.207) | 6.21 (2.595 to 10.349) | 2.37 (0.460 to 2.694) | 2.66 (0.427 to 6.341) |
Percentage of participants who had a CR or PR as BOR using LRC, 2014 (based on PET-CT and CT responses). CR (per PET-CT): complete MR in lymph nodes and extra lymphatic sites with a score of 1, 2, or 3 with or without residual mass; no new lesions and no evidence of FDG-avid disease. CR (CT-response): target nodes/nodal masses of lymph nodes, extralymphatic sites regressed to \<=1.5cm LDi; absence of non-measured lesion; organ enlargement regressed to normal; no new lesions; normal bone marrow morphology. PR (per PET-CT): partial MR in lymph nodes and extral ymphatic sites; no new lesions and residual uptake higher than uptake. PR (per CT): lymph nodes, extralymphatic sites \>=50% decrease in SPD, extranodal sites; if lesion is too small to measure on CT, assign 5mm\*5mm as default; if no longer visible:0\*0mm; Node\>5mm\*5mm but smaller than normal, used actual measurement; absent/regressed non-measured lesions; no increase; spleen regressed by\>50% or no new lesions.
| percentage of participants | Cohort A1: cHL: Isatuximab + Cemiplimab | Cohort A2: cHL: Isatuximab + Cemiplimab |
|---|---|---|
| Cohort A1 and A2: Percentage of Participants With Objective Response | 55.6 (34.1 to 75.6) | 33.3 (12.3 to 60.9) |
Percentage of participants who had a CR as a BOR using the LRC, 2014 (based on PET-CT and CT responses). Per LRC, CR based on PET-CT was defined as complete MR in lymph nodes and extralymphatic sites with a score of 1, 2, or 3 with or without residual mass, on 5PS, where, 1= no uptake above background; 2 = uptake \<=mediastinum; 3 = uptake \> mediastinum but \<= liver; 4 = uptake moderately \> liver; 5 = uptake markedly higher than liver and/or new lesions; no new lesions and no evidence of FDG-avid disease in bone marrow. CR based on CT-response was defined as target nodes/nodal masses of lymph nodes, extralymphatic sites regressed to \<=1.5 cm in longest dimension transverse diameter of lesion (LDi); absence of non-measured lesion; organ enlargement regressed to normal; no new lesions; normal bone marrow morphology; if indeterminate, immunohistochemistry negative.
| percentage of participants | Cohort A1: cHL: Isatuximab + Cemiplimab | Cohort A2: cHL: Isatuximab + Cemiplimab |
|---|---|---|
| Cohort A1 and A2: Percentage of Participants With Complete Response | 27.8 | 16.7 |
Collected over From first dose of study drug up to 30 days after the last dose of study drug (maximum duration: up to 103 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A1: cHL: Isatuximab + Cemiplimab | 4/18 (22.2%) | 3/18 (16.7%) | 16/18 (88.9%) |
| Cohort A2: cHL: Isatuximab + Cemiplimab | 0/12 (0%) | 2/12 (16.7%) | 12/12 (100%) |
| Cohort B: DLBCL: Isatuximab + Cemiplimab | 12/17 (70.6%) | 10/17 (58.8%) | 17/17 (100%) |
| Cohort C: PTCL: Isatuximab + Cemiplimab | 6/11 (54.5%) | 7/11 (63.6%) | 10/11 (90.9%) |
| Event | Cohort A1: cHL: Isatuximab + Cemiplimab | Cohort A2: cHL: Isatuximab + Cemiplimab | Cohort B: DLBCL: Isatuximab + Cemiplimab | Cohort C: PTCL: Isatuximab + Cemiplimab |
|---|---|---|---|---|
| Urinary Tract Infection BacterialInfections and infestations | 0/18 | 0/12 | 2/17 | 0/11 |
| Disease ProgressionGeneral disorders | 0/18 | 0/12 | 2/17 | 0/11 |
| Meningitis AsepticInfections and infestations | 0/18 | 0/12 | 0/17 | 1/11 |
| Pneumonia BacterialInfections and infestations | 0/18 | 0/12 | 0/17 | 1/11 |
| Pneumonia Respiratory Syncytial ViralInfections and infestations | 0/18 | 0/12 | 0/17 | 1/11 |
| Urinary Tract InfectionInfections and infestations | 0/18 | 0/12 | 1/17 | 1/11 |
| AnaemiaBlood and lymphatic system disorders | 0/18 | 0/12 | 0/17 | 1/11 |
| Peripheral Sensorimotor NeuropathyNervous system disorders | 0/18 | 0/12 | 0/17 | 1/11 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 0/18 | 0/12 | 0/17 | 1/11 |
| Gastrointestinal HaemorrhageGastrointestinal disorders | 0/18 | 0/12 | 0/17 | 1/11 |
| Event | Cohort A1: cHL: Isatuximab + Cemiplimab | Cohort A2: cHL: Isatuximab + Cemiplimab | Cohort B: DLBCL: Isatuximab + Cemiplimab | Cohort C: PTCL: Isatuximab + Cemiplimab |
|---|---|---|---|---|
| Infusion Related ReactionInjury, poisoning and procedural complications | 7/18 | 9/12 | 8/17 | 7/11 |
| NauseaGastrointestinal disorders | 1/18 | 6/12 | 4/17 | 1/11 |
| DiarrhoeaGastrointestinal disorders | 4/18 | 4/12 | 4/17 | 2/11 |
| Oedema PeripheralGeneral disorders | 3/18 | 0/12 | 5/17 | 1/11 |
| PyrexiaGeneral disorders | 4/18 | 3/12 | 3/17 | 3/11 |
| Upper Respiratory Tract InfectionInfections and infestations | 0/18 | 3/12 | 1/17 | 1/11 |
| PruritusSkin and subcutaneous tissue disorders | 2/18 | 3/12 | 0/17 | 1/11 |
| Abdominal PainGastrointestinal disorders | 0/18 | 0/12 | 4/17 | 0/11 |
| FatigueGeneral disorders | 0/18 | 1/12 | 4/17 | 2/11 |
| Back PainMusculoskeletal and connective tissue disorders | 4/18 | 1/12 | 2/17 | 0/11 |
Analysis was performed on all treated population which included all participants who signed the study informed consent and received at least 1 dose of the study treatment, either isatuximab or cemiplimab.
| Age, Continuous(years) | Cohort A1: cHL: Isatuximab + Cemiplimab | Cohort A2: cHL: Isatuximab + Cemiplimab | Cohort B: DLBCL: Isatuximab + Cemiplimab | Cohort C: PTCL: Isatuximab + Cemiplimab | Total |
|---|---|---|---|---|---|
| Mean | 44.8 ± 20.1 | 38.0 ± 15.5 | 60.8 ± 14.2 | 65.5 ± 8.8 | 52.0 ± 18.8 |
| Sex: Female, Male(Participants) | Cohort A1: cHL: Isatuximab + Cemiplimab | Cohort A2: cHL: Isatuximab + Cemiplimab | Cohort B: DLBCL: Isatuximab + Cemiplimab | Cohort C: PTCL: Isatuximab + Cemiplimab | Total |
|---|---|---|---|---|---|
| Female | 8 | 5 | 5 | 4 | 22 |
| Male | 10 | 7 | 12 | 7 | 36 |
| Race (NIH/OMB)(Participants) | Cohort A1: cHL: Isatuximab + Cemiplimab | Cohort A2: cHL: Isatuximab + Cemiplimab | Cohort B: DLBCL: Isatuximab + Cemiplimab | Cohort C: PTCL: Isatuximab + Cemiplimab | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 1 | 4 | 2 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 12 | 4 | 8 | 7 | 31 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 5 | 7 | 5 | 2 | 19 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Dec 2018 to primary completion in Nov 2022, 46 months.
Results were first posted in Oct 2023, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Isatuximab